South Dakota is currently home to 325 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Sioux Falls, Rapid City, Aberdeen and Watertown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Contoura With Phorcides Compared to Wavefront Optimized LASIK
NCT05486546
Recruiting
Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.
Gender:
All
Ages:
Between 21 years and 38 years
Trial Updated:
04/24/2023
Locations: Vance Thompson Vision, Sioux Falls, South Dakota
Conditions: Myopia, Astigmatism
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Prairie Lakes Health Care System, Watertown, South Dakota
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
Conditions: Colorectal Cancer
Register for Updates
myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
NCT05693831
Recruiting
The purpose of this study is to determine the benefit of Cellworks Singula™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications who have already received first-line therapy. The study is also to determine the benefit of Cellworks Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of relapsed or refractory pan-cancer indications. The primary objective of this study is to survey phy... Read More
Gender:
All
Ages:
All
Trial Updated:
01/20/2023
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Cancer, Relapsed Cancer, Refractory Cancer
Register for Updates
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
NCT04900519
Recruiting
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Sanford Health, Sioux Falls, South Dakota
Conditions: Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
Register for Updates
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
NCT02075775
Recruiting
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to complete the RAND-36, ASES, Shoulder Activity, EQ-5D and WOSI outcome measures, as well as demographic and socioeconomic information. Surgeons will complete a form after surgery with information on radiogra... Read More
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
11/07/2022
Locations: Orthopedic Institute, Sioux Falls, South Dakota
Conditions: Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Register for Updates
An Observational, Qualitative Study Assessing Eye Drop Administration
NCT05307081
Recruiting
This is a prospective, observational, consecutive, qualitative, multicenter study. Based on the available published evidence that supports patient challenges with eyedrop administration, the purpose of this video-capture study is to evaluate a more real-world population of consenting patients, regardless of age, with or without visual impairment, at routine eyecare visits. To date, no studies have been performed evaluating a real-world population consisting of daily routine eyecare clinic patie... Read More
Gender:
All
Ages:
All
Trial Updated:
09/13/2022
Locations: Vance Thompson Vision, Sioux Falls, South Dakota
Conditions: Ocular Injury
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Rapid City Medical Center, Rapid City, South Dakota
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting
NCT04900844
Recruiting
The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS) to a performance goal developed from published CAS literature.
Gender:
All
Ages:
Between 19 years and 80 years
Trial Updated:
06/16/2022
Locations: Avera Heart Hospital, Sioux Falls, South Dakota
Conditions: Carotid Artery Stenosis
Register for Updates
Comparison Of A Novel Sling With A Traditional Abduction Sling After Shoulder Surgery
NCT05274737
Recruiting
The objective of this study is to determine if the novel shoulder sling has higher patient satisfaction compared to a traditional, abduction sling with at least equivalent postoperative outcomes after arthroscopic rotator cuff repair and total shoulder arthroplasty.
Gender:
All
Ages:
All
Trial Updated:
06/13/2022
Locations: Orthopedic Institute, Sioux Falls, South Dakota
Conditions: Rotator Cuff Tears, Osteo Arthritis Shoulders
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Avera Medical Group, Sioux Falls, South Dakota
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Sanford Health, Sioux Falls, South Dakota
Conditions: Solid Tumors, GI Cancer
Register for Updates